Identification of a novel LRRC4C-ALK fusion in lung adenocarcinoma and outcome of the response to anaplastic lymphoma kinase inhibitors

J Gene Med. 2021 Mar;23(3):e3316. doi: 10.1002/jgm.3316. Epub 2021 Feb 8.
No abstract available

Keywords: ALK; ALK inhibitors; fusion; lung adenocarcinoma; rearrangement.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy
  • Adenocarcinoma of Lung / genetics*
  • Adult
  • Anaplastic Lymphoma Kinase / antagonists & inhibitors
  • Antineoplastic Agents / therapeutic use
  • Gene Fusion*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Male
  • Nerve Tissue Proteins / genetics*
  • Protein Kinase Inhibitors / therapeutic use*
  • Receptors, Cell Surface / genetics*

Substances

  • Antineoplastic Agents
  • LRRC4C protein, human
  • Nerve Tissue Proteins
  • Protein Kinase Inhibitors
  • Receptors, Cell Surface
  • Anaplastic Lymphoma Kinase